THE INTESTINAL EPITHELIUM, particularly in the colon, faces unique challenges in maintaining cell and tissue homeostasis. Unlike most other epithelia in the body, it is constantly barraged with a soup of microbes and their products. These have the potential to activate inflammation and immune responses. Indeed, the normal physiological state of the intestine appears to be one of controlled inflammation, with a variety of immune and inflammatory effector cells located in the lamina propria immediately adjacent to the epithelium, even in health. This may reflect a state of readiness, where sufficient numbers of phagocytes and other antimicrobial effectors are present to deal quickly with any possible microbial invasion before it becomes systemic. However, in susceptible individuals, the regulatory controls on this “physiological” inflammation break down, likely due to either immune defects and/or defects in the barrier properties of the epithelium itself, and chronic, pathological inflammation ensues (15). This chronic inflammation, which is driven by immune responses to the enteric flora, establishes a vicious cycle because tissue injury, particularly to the epithelium, further compromises the ability of the gut to exclude immunostimulatory molecules (3, 11, 12). There is now substantial evidence that this type of cycle is centrally involved in the pathogenesis of important digestive diseases such as ulcerative colitis and Crohn’s disease, which may also predispose sufferers to subsequent development of colon cancer (7). However, the mechanisms that normally allow individuals to restrain immune responses to the enteric flora, and thus limit inflammation, are still poorly understood. Inflammatory responses in the gut (as in other tissue sites) as well as progression to malignancy, are pivotally controlled by the transcription factor NF-B (8). This factor is normally held in an inactive state in the cell cytosol as a complex with its inhibitor, IB. In response to a variety of extracellular signals, including those delivered by microbial products or inflammatory cytokines, IB is phosphorylated, and thereby targeted for ubiquitination and subsequent degradation by the proteosome. This frees NF-B to translocate to the nucleus, where it binds to the promoter regions and evokes expression of a series of target genes that perpetuate the inflammatory response, including chemokines such as IL-8 that stimulate the influx of inflammatory cell types. In addition, NF-B can trigger the production of signals that limit epithelial apoptosis, and may be involved in the predisposition to malignancy that accompanies chronic intestinal inflammation (6). Thus NF-B can be considered a master regulator that can both initiate and
Read full abstract